BCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
BioCryst Pharmaceuticals's average Accounts Payable for the three months ended in Sep. 2024 was $10.6 Mil. BioCryst Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2024 was $3.2 Mil. Hence, BioCryst Pharmaceuticals's Days Payable for the three months ended in Sep. 2024 was 300.60.
The historical rank and industry rank for BioCryst Pharmaceuticals's Days Payable or its related term are showing as below:
During the past 13 years, BioCryst Pharmaceuticals's highest Days Payable was 10505.72. The lowest was 590.49. And the median was 1169.44.
BioCryst Pharmaceuticals's Days Payable declined from Sep. 2023 (982.22) to Sep. 2024 (300.60). It may suggest that BioCryst Pharmaceuticals accelerated paying its suppliers.
The historical data trend for BioCryst Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Payable | Get a 7-Day Free Trial | 968.22 | 3,560.82 | 1,168.79 | 1,166.96 | 1,380.16 |
BioCryst Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Days Payable | Get a 7-Day Free Trial | 982.22 | 876.82 | 1,075.17 | 518.24 | 300.60 |
For the Biotechnology subindustry, BioCryst Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioCryst Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as
Days Payable (A: Dec. 2023 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Dec. 2022 ) | + | Accounts Payable (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (14.356 | + | 20.893) | / | 2 ) | / | 4.661 | * | 365 |
= | 17.6245 | / | 4.661 | * | 365 | ||||
= | 1,380.16 |
BioCryst Pharmaceuticals's Days Payable for the quarter that ended in Sep. 2024 is calculated as:
Days Payable (Q: Sep. 2024 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Jun. 2024 ) | + | Accounts Payable (Q: Sep. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Sep. 2024 ) | * | Days in Period |
= | ( (7.786 | + | 13.482) | / | 2 ) | / | 3.228 | * | 365 / 4 |
= | 10.634 | / | 3.228 | * | 365 / 4 | ||||
= | 300.60 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Amy E Mckee | director | 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703 |
Machelle Sanders | director | C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560 |
Theresa Heggie | director | 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703 |
Alan G Levin | director | ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050 |
Steve Aselage | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Nancy J Hutson | director | 64 MONTAUK AVENUE, STONINGTON CT 06378 |
Vincent Milano | director | C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341 |
Helen M. Thackray | director | C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
Anthony Doyle | officer: Chief Financial Officer | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Steven K Galson | director | C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703 |
Charles K Gayer | officer: Vice President and CCO | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Alane P Barnes | officer: VP, General Counsel & Corp Sec | 1929 BRASSFIELD ROAD, RALEIGH NC 27614 |
Jon P Stonehouse | director, officer: CEO | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
Michael L Jones | officer: Exec Director, Finance - PAO | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Yarlagadda S Babu | officer: VP Drug Discovery | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
From GuruFocus
By Marketwired • 10-21-2024
By GuruFocus News • 11-05-2024
By GuruFocus Research • 08-06-2024
By GuruFocus News • 11-05-2024
By Marketwired • 09-06-2024
By GuruFocus News • 11-07-2024
By Marketwired • 10-02-2024
By Marketwired • 08-02-2024
By Marketwired • 09-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.